A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies ...

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype.

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront ...

An update from Sino Biopharmaceutical ( (HK:1177)) is now available. Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported positive Phase III results for TQB3454, an IDH1 inhibitor ...

A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those ...

This study reclassified patients according to modern WHO Classification criteria by integrating multi-dimensional molecular markers. It thoroughly investigated the clinical and molecular disparities ...

A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected ...

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper ...

Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it ...

The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended ...

Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 ...